A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009495/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this phase 3 study is to investigate the efficacy and safety, including
immunogenicity, thrombogenicity and hypersensitivity reactions, as well as pharmacokinetics
(PK), health related quality of life (HRQoL) and pharmacoeconomics of prophylactic treatment
with recombinant von Willebrand factor (rVWF) (vonicog alfa) in adult participants with
severe von Willebrand disease (VWD).
提供机构：
Vivli
创建时间：
2023-12-15
